The European Medicines Agency (EMA), the European Union’s drug regulator, has approved the widespread use of the Imvanex vaccine against monkeypox for adults.
“Report” reports that this was stated in the agency’s statement.
The drug has been approved for the prevention of smallpox in the EU since 2013.
The agency based its recommendations on data from several studies showing that Imvanex is effective in preventing monkeypox in humans.
According to experts, the side effects of the drug are mild to moderate, and the benefits of using it outweigh the risks. Based on these recommendations, necessary changes will be made to the instructions for the use of the drug in the near future.